Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa.

Julg B, Poole D, Ghebremichael M, Castilla C, Altfeld M, Sunpath H, Murphy RA, Walker BD.

PLoS One. 2012;7(2):e31161. doi: 10.1371/journal.pone.0031161. Epub 2012 Feb 14.

2.

Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration.

Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, Nash D, Sprinz E, Dabis F, Harrison LH, Schechter M.

J Acquir Immune Defic Syndr. 2007 May 1;45(1):52-9.

PMID:
17460471
3.

Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients.

Maskew M, Brennan AT, Westreich D, McNamara L, MacPhail AP, Fox MP.

J Womens Health (Larchmt). 2013 Feb;22(2):113-20. doi: 10.1089/jwh.2012.3585. Epub 2013 Jan 25.

4.

Growth in HIV-infected children on long-term antiretroviral therapy.

Feucht UD, Van Bruwaene L, Becker PJ, Kruger M.

Trop Med Int Health. 2016 May;21(5):619-29. doi: 10.1111/tmi.12685. Epub 2016 Mar 21.

5.
6.

Hepatitis B and C Co-Infection in HIV Patients from the TREAT Asia HIV Observational Database: Analysis of Risk Factors and Survival.

Chen M, Wong WW, Law MG, Kiertiburanakul S, Yunihastuti E, Merati TP, Lim PL, Chaiwarith R, Phanuphak P, Lee MP, Kumarasamy N, Saphonn V, Ditangco R, Sim BL, Nguyen KV, Pujari S, Kamarulzaman A, Zhang F, Pham TT, Choi JY, Oka S, Kantipong P, Mustafa M, Ratanasuwan W, Durier N, Chen YM.

PLoS One. 2016 Mar 2;11(3):e0150512. doi: 10.1371/journal.pone.0150512. eCollection 2016.

8.

Predictors of poor CD4 and weight recovery in HIV-infected children initiating ART in South Africa.

Zanoni BC, Phungula T, Zanoni HM, France H, Cook EF, Feeney ME.

PLoS One. 2012;7(3):e33611. doi: 10.1371/journal.pone.0033611. Epub 2012 Mar 16.

9.

A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.

Rajesh R, Vidyasagar S, Varma DM, Naik A, Hegde BM, Guddattu V, Kamath A.

Int J Risk Saf Med. 2013 Jan 1;25(1):53-65. doi: 10.3233/JRS-130580.

PMID:
23442298
10.

Zidovudine impairs immunological recovery on first-line antiretroviral therapy: collaborative analysis of cohort studies in southern Africa.

Wandeler G, Gsponer T, Mulenga L, Garone D, Wood R, Maskew M, Prozesky H, Hoffmann C, Ehmer J, Dickinson D, Davies MA, Egger M, Keiser O; IeDEA Southern Africa Collaboration.

AIDS. 2013 Sep 10;27(14):2225-32. doi: 10.1097/QAD.0b013e328362d887.

11.

CD4 and viral load dynamics in antiretroviral-naïve HIV-infected adults from Soweto, South Africa: a prospective cohort.

Martinson NA, Gupte N, Msandiwa R, Moulton LH, Barnes GL, Ram M, Gray G, Hoffmann C, Chaisson RE.

PLoS One. 2014 May 15;9(5):e96369. doi: 10.1371/journal.pone.0096369. eCollection 2014. Erratum in: PLoS One. 2015;10(7):e0133093. PLoS One. 2015;10(6):e0130509.

12.

Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults.

Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML.

PLoS One. 2011;6(7):e21795. doi: 10.1371/journal.pone.0021795. Epub 2011 Jul 1.

13.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
14.

CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.

Li X, Margolick JB, Jamieson BD, Rinaldo CR, Phair JP, Jacobson LP.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):421-8. doi: 10.1097/QAI.0b013e31821e9f21.

15.

Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands.

Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM.

J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):943-50.

PMID:
15220701
16.

Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa.

Lawn SD, Myer L, Edwards D, Bekker LG, Wood R.

AIDS. 2009 Aug 24;23(13):1717-25. doi: 10.1097/QAD.0b013e32832d3b6d.

17.

Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy.

Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, Weber JN.

AIDS. 2002 May 24;16(8):1139-46.

PMID:
12004272
18.

Who starts antiretroviral therapy in Durban, South Africa?... not everyone who should.

Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM, Holst H, Ross D, Katz JN, Walensky RP, Freedberg KA, Losina E.

AIDS. 2010 Jan;24 Suppl 1:S37-44. doi: 10.1097/01.aids.0000366081.91192.1c.

19.

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC.

J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8. doi: 10.1097/QAI.0b013e31816856c5.

PMID:
18285713
20.

Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.

Rizzardi GP, Tambussi G, Bart PA, Chapuis AG, Lazzarin A, Pantaleo G.

AIDS. 2000 Oct 20;14(15):2257-63.

PMID:
11089613

Supplemental Content

Support Center